This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active pharmaceutically active substance and/or label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for prophylaxis, therapy, diagnosis or theragnosis, in particular for prophylactic or therapeutic vaccination, therapy of cancer, particularly metastatic cancer or inflammatory diseases.

The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

The present disclosure is directed to the TNF-related apoptosis inducing ligand (TRAIL) fusions with positively charged proteins, neutrophils engineered to express and secrete such fusions in the context of neutrophil extracellular traps, and methods of use thereof in the treatment of cancer.

Methods of tissue grafting, and more particularly methods for enhancing tissue graft revascularization, e.g., host engagement of pre-existing graft blood vessels.

The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.

This disclosure provides genetically engineered immune cells that express an anti-GD2 chimeric antigen receptor, methods of generating these cells, and methods of treating tumors using the genetically engineered cells.

In an embodiment, present invention relates to a method of generating, ex vivo production of soluble Lox-1 (sLox-1), comprising: introducing a sample containing blood into a device; adding a coagulation enhancing material in the sample to form a cultured blood clot; incubating the cultured blood clot in the device at a temperature greater than 25? C. and less than 45? C. for at least 2 hours to allow production of Lox-1 from neutrophils of blood and to shed the sLox-1 outside the cultured blood clot; and collecting sLox-1 shedded in the device, wherein the method is configured to shed sLox-1 more than fresh blood.

A method for producing non-human conditionally immortalized mast cell progenitors comprises: introducing a nucleic acid molecule comprising an inducible homeobox gene into myeloid progenitor cells, wherein said myeloid progenitor cells are derived from a non-human animal and are engineered to express a heterologous high-affinity IgE receptor alpha subunit (Fc?RI?); and selecting for cells which contain the nucleic acid molecule. The non-human conditionally immortalized mast cell progenitors may be cultured to obtain differentiated mast cells. The mast cells find utility in assays for the determination of IgE mediated allergies.

Disclosed herein are methods for generating universal MHC/HLA-compatible hematopoietic progenitor cells and methods for generating custom patient-specific MHC/HLA-compatible hematopoietic progenitor cells. Compositions comprising the universal and custom hematopoietic progenitor cells and therapeutic applications thereof are also disclosed.